ABOUT RESEARCH INVESTORS CAREERS CONTACT

NGM Biopharmaceuticals, Inc. is dedicated to the discovery and development of transformational medicines. Relying on human clinical and genetic observations, the Company has established a unique research and discovery platform to identify and validate novel targets and factors that impact the underlying etiology of metabolic diseases. NGM’s strategy is to elucidate the roles of these previously unidentified or unexplored hormones, receptors and factors in the systemic regulation of metabolism.

Using this integrated approach NGM is generating a pipeline of new drug candidates as novel treatments for diseases such as diabetes, obesity, muscle wasting and cardiovascular disease. Founded in 2008, NGM has world-class scientists and an accomplished executive team with broad experience in building and managing biotechnology companies. NGM is headquartered in South San Francisco, California.

RECENT NEWS

NGM Biopharmaceuticals Raises $51 Million in Series B Financing and Appoints New Board Member

March 15, 2010

NGM Appoints Dr. Arthur D. Levinson, former Genentech CEO, to its Board of Directors

October 21, 2009

NGM Appoints Helen S. Kim as
Chief Business Officer

September 1, 2009

World-renowned bariatric surgeon, Dr. Francesco Rubino, joins NGM’s elite Scientific Advisory Board

June 19, 2008